Citations

Clear

97 citation(s) found for "Ghanem, R".

Global Variations in Practices After Bariatric and Metabolic Surgery; the PARTNER study
Clyde, Danielle , Grant, Callum, Canales, Juan Andres Aguiar, Adib, Reza, Baig, Sarfaraz Jalil , Bhasker, Aparna Govil , Beaux, Andrew de, Drummond, Gillian, Fawal, Hayssam, Goodpaster, Kasey , Hopkins, George, Jatana, Anita , Kothari, Shanu N. , Kow, Lillian, Faria, Sílvia Leite , Madhok, Brij, Mahon, David, Miller, Karl , Nimeri, Abdelrahman , O’Kane, Mary , Poggi, Luis , Ratcliffe, Denise , Sarkar, Rupa , Shenfine, Jon, Sogg, Stephanie , Suter, Michel , Taha, Safwan , Voon, Kelvin , Lamb, Peter , Mahawar, Kamal , Grant, Callum, Canales, Juan Andres Aguiar, Cameron, David, Copăescu, Cătălin , Clare, Ken , Fried, Martin , Graham, Yitka N. H. , Goel, Ramen , Hazebroek, Eric J. , Husain, Farah Anwari , Joyce, Brian, Kermansaravi, Mohammad , Miras, Alexander Dimitri , Moizé, Violeta , Neto, Manoel Galvão , Peterli, Ralph , Sakran, Nasser , Salminen, Paulina , Singhal, Rishi , Stenberg, Erik , Tahrani, Abd A. , Vilallonga, Ramón , Welbourn, Richard , Zerrweck, Carlos , Moussa, Osama , Byrne, James Patrick , Parmar, Chetan D. , Ghanem, Omar M. , Robertson, Andrew G. , Yang, Wah

Mayo Clinic

No container title available | August 6, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-6779565/v1 Get It

Abstract Background: With over 1 billion individuals affected globally, obesity and obesity related diseases is now a leading cause of death. Metabolic and bariatric surgery (MBS) has emerged as a cornerstone intervention for severe obesity and its associated comorbidities. Despite its efficacy, postoperative care and follow-up after MBS remains highly variable worldwide. Objective: The PARTNER study aimed to evaluate global clinical practices in the postoperative management following MBS by surveying multidisciplinary healthcare professionals . Methods: This study was an international online survey conducted between October 2024 and January 2025. A multidisciplinary team developed the questionnaire based on existing literature and international guidelines. The survey assessed five domains: follow-up care, postoperative treatment, dietary management, patient support, and measurement of surgical outcomes. Responses were analysed descriptively. Results: A total of 262 responses were received from 62 countries. Most respondents were bariatric surgeons (72.1%) working in public healthcare systems (73.3%). While 78.7% reported conducting three-month postoperative reviews, only 23.7% offered indefinite follow-up. Hybrid models of care (virtual and in-person) were common (56.9%). VTE prophylaxis and postoperative PPI use were recommended by 64.1% and 84.3% respectively. Nearly all respondents (98.1%) provided dietary advice, with protein and micronutrient supplementation widely endorsed. Only 56.1% routinely referred patients for psychological follow-up. Definitions of surgical success and failure varied widely, with inconsistent objective outcome measures. Conclusion: The PARTNER study reveals significant international variation in postoperative management practices following MBS. These findings underscore the need for more standardized, evidence-based guidelines to improve long-term outcomes and equity of care worldwide.
Multicenter Insights into Peritoneal Dialysis for Autosomal Dominant Polycystic Kidney Disease
Debeh, Fadi George Munairdjy , Ghanem, Ahmad , Rangarajan, Vineetha, Borghol, Abdul Hamid , Paul, Stefan , Alkhatib, Bassel , Nader, Nay , Antoun, Mikhail D., Hanna, Dana, Souvalian, Levon , Li, Zhuo, Gregory, Adriana , Kline, Timothy L. , Manohar, Sandhya , Porter, Ivan E. , Dillon, John , Kattah, Andrea G. , Khalillullah, Sayeed , Baker, Lyle W. , Trautman, Christopher L. , Aslam, Nabeel , Li, Zhuo , Munairdjy Debeh, Fadi George , Bou Antoun, Marie Therese , Kline, Timothy L , Mao, Michael A , Manohar, Sandhya , Porter, Ivan , Dillon, John J , Kattah, Andrea G , Khalillullah, Sayeed , Baker, Lyle Wesley , Trautman, Christopher L , Chebib, Fouad T , Aslam, Nabeel , Rangarajan, Vineetha, Nader, Nay , Hanna, Dana, Mao, Michael A. , Hickson, LaTonya J. , Chebib, Fouad T.

Mayo Clinic

Kidney360 | July 7, 2025 | Volume: 6 | Issue: 11 | Pages: 1918-1927

10.34067/kid.0000000888 | PMID 40622773 Get It

Key Points This study demonstrates that peritoneal dialysis is a safe and feasible option for patients with autosomal dominant polycystic kidney disease, even with high cystic organ volumes. Larger organ volumes, including height-adjusted cumulative kidney and liver volume, were not associated with increased peritoneal dialysis–related complications. Background Autosomal dominant polycystic kidney disease (ADPKD) is the most prevalent genetic kidney disorder and the fourth leading cause of kidney failure. Peritoneal dialysis (PD), preferred for its home-based convenience and cost-effectiveness, is often underutilized in ADPKD because of concerns over enlarged kidneys and heightened risk of complications. Methods This retrospective cohort study used data from the Mayo Clinic Polycystic Kidney Disease Database to evaluate individuals with ADPKD undergoing PD. We analyzed demographics, clinical parameters, and PD-related parameters. Complications were correlated with kidney and liver volumes derived from pre-kidney failure imaging. Results A total of 155 individuals with ADPKD on PD were included, of whom 45.1% were male. The mean age at PD initiation was 54.3±12.8 years, and the mean body mass index was 28.0±7.0 kg/m 2 . The median duration of PD was 24.3 months (interquartile range [IQR], 10.7–43.1), with 21.9% transitioning to hemodialysis. The most common complications were abdominal hernias (30.3%) and peritonitis (23.9%), with a peritonitis rate of 0.11 episodes per patient-year. Imaging analyses performed on a subset of 50 patients showed a median height-adjusted total kidney liver volume of 2731.9 ml/m (IQR, 2102.5–3131.1) and a median height-adjusted total kidney volume of 1303.5 ml/m (IQR, 733.1–1829.4). Kaplan–Meier analysis demonstrated no differences in complications rates on the basis of height-adjusted total kidney liver volume or height-adjusted total kidney volume (above versus below median values) or body mass index categories. Multivariate Cox regression analysis revealed that higher height-adjusted cumulative organ volume was associated with a lower risk of PD-related complications (hazard ratio=0.56, P = 0.026). Conclusions PD is a safe and feasible treatment option for patients with ADPKD, with no increased risk of PD-related complications associated with larger height-adjusted cumulative organ volumes. Infectious complication rates in this cohort were within International Society of Peritoneal Dialysis guideline thresholds, further supporting the safety of PD in this population.
Pain Management in Autosomal Dominant Polycystic Kidney Disease
Borghol, Abdul Hamid , Debeh, Fadi George Munairdjy , Ghanem, Ahmad , Antoun, Mikhail D., Rangarajan, Vineetha, Mina, Jonathan , Hassanein, Mohamed , Baker, Lyle W. , Gupta, Sahil , Mao, Shennen A. , Munairdjy Debeh, Fadi George , Bou Antoun, Marie Therese , Hunt, Christine , Hogan, Marie C , Mao, Michael A , Chebib, Fouad T , Baker, Lyle Wesley , Mao, Shennen A , Rangarajan, Vineetha, Hogan, Marie C. , Mao, Michael A. , Chebib, Fouad T.

Mayo Clinic

Kidney360 | July 7, 2025 | Volume: 6 | Issue: 9 | Pages: 1618-1631

10.34067/kid.0000000907 | PMID 40622770 Get It

Autosomal dominant polycystic kidney disease (ADPKD) is the most common genetic kidney disorder. It is primarily caused by pathogenic variants in the PKD1 or PKD2 genes. This leads to the development of numerous kidney cysts, which can result in kidney enlargement and progression to kidney failure. Pain is a common symptom in ADPKD and can negatively affect quality of life (QOL). This pain is often due to the continuous growth of kidney and liver cysts or associated cystic complications. We present a case of a 29-year-old woman with ADPKD who experienced chronic, refractory right-sided flank pain that significantly affected her QOL. Her pain persisted despite taking daily multimodal analgesics and undergoing multiple invasive interventions. She had an unusual asymmetric disease with the right kidney accounting for only 24% of her kidney function. After exhausting all other pain control strategies, she underwent right nephrectomy and partial hepatectomy, which led to substantial improvement in pain and QOL. This review describes the causes, manifestations, and management strategies for abdominal and/or flank pain in ADPKD, including a practical stepwise algorithm to guide clinicians in managing pain and improve QOL of patients with ADPKD. Pain in ADPKD can either be acute or chronic and can lead to significant physical and psychologic distress. Effective pain management in ADPKD requires a multidisciplinary approach, incorporating both nonpharmacologic and pharmacologic interventions such as gabapentin or tolvaptan in select cases. Interventions considered in ADPKD pain control include cyst aspiration with sclerotherapy, celiac plexus blockade, spinal cord stimulation, renal denervation, or nephrectomy.
Secondary Peristalsis Is More Affected Than Primary Peristalsis by Increased Intragastric Pressure After Metabolic Bariatric Surgery: Findings From Functional Lumen Imaging Probe and High‐Resolution Esophageal Manometry
Perananthan, Varan , Hanscom, Mark, Razzak, Farah Abdul, Mrad, Rudy, Abboud, Donna Maria , Annan, Karim Al , Kassmeyer, Blake , Perananthan, Varan , Al Annan, Karim, Kerbage, Anthony , Storm, Andrew, Vargas Valls, Eric J, Abboud, Donna M , Ravi, Karthik , Hanscom, Mark , Razzak, Farah Abdul, Storm, Andrew C. , Vargas, Eric J. , Ghanem, Omar M. , Dayyeh, Barham K. Abu

Mayo Clinic

Neurogastroenterology & Motility | June 27, 2025 | Volume: 37 | Issue: 11 | Pages: No page available

10.1111/nmo.70110 | PMID 40572029 Get It

ABSTRACTIntroductionEsophageal dysmotility following metabolic bariatric surgery (MBS) may relate to decreased gastric compliance. We investigated high‐resolution esophageal manometry (HRM) and secondary peristalsis assessed by functional lumen imaging probe (FLIP) and their association with intragastric pressure after MBS.MethodsPatients undergoing HRM, FLIP, and barium esophagram (BE) after MBS were included. HRM metrics and proximal intragastric pressure at baseline (IGP baseline), during wet swallow‐induced esophagogastric junction relaxation (IGP EGJ opening), and following wet swallow‐induced esophagogastric junction opening with subsequent closure (IGP post EGJ closure) were measured. Contractile response was assessed during FLIP.ResultsForty patients (26 Roux en Y gastric bypass, 14 sleeve gastrectomy) with FLIP a median of 4 years after MBS, were identified. HRM was normal or consistent with ineffective esophageal motility (IEM) in 33 (82.5%) patients, while the contractile response on FLIP was abnormal (disordered/impaired, absent, or spastic reactive) in 28 (70%). Delayed emptying on BE was numerically more frequent with abnormal FLIP (6% vs. 0%, p = 0.08). IGP post‐EGJ closure (median 21.8 vs. 15 mmHg, p = 0.03) and ∆ IGP post‐EGJ closure—IGP baseline (median 4 vs. 0 mmHg, p = 0.02) were greater and predictive of abnormal contractility on FLIP (OR 1.11, 95% CI 1.00–1.2, p = 0.03 and OR 1.6, 95% CI 1.07–2.39, p = 0.003, respectively).DiscussionAbnormal contractility on FLIP, reflecting disordered secondary peristalsis, frequently occurs despite normal HRM findings after MBS. Secondary peristalsis may be associated with reduced gastric compliance, reflected by elevated proximal intragastric pressure. FLIP contractility could serve as an early marker for post‐MBS esophageal dysfunction.
Financial buy-in does not affect outcomes of endoscopic sleeve gastroplasty: Retrospective cohort
Sayegh, Lea N. , Akiki, Karl, Annan, Karim Al , Gala, Khushboo , Ghanem, Omar M. , Sayegh, Lea Nicole , Al Annan, Karim, Abi Mosleh, Kamal , Mundi, Manpreet, Storm, Andrew C , Akiki, Karl, Salameh, Yara , Mosleh, Kamal Abi , Mundi, Manpreet S. , Dayyeh, Barham K. Abu , Storm, Andrew C.

Mayo Clinic

Endoscopy International Open | June 10, 2025 | Volume: 13 | Issue: CP | Pages: No page available

10.1055/a-2631-7439 | PMID 40726523 Get It

AbstractEndoscopic sleeve gastroplasty (ESG) is an effective treatment for obesity but typically is not covered by insurance. It is not known whether patients with financial investment in their endoscopic procedure are more likely to achieve and/or maintain weight loss as compared with those who have no financial buy-in. We aimed to compare treatment adherence and outcomes between patients paying out-of-pocket (OOP) and those who underwent ESG as part of any clinical trial where costs were covered by a study protocol (no payment; NP).Data were collected via retrospective chart review. One hundred sixty-four patients who had an ESG with at least 6 months of follow-up were included. Repeated measures with generalized linear model were used to evaluate weight loss at different time points after ESG and labs values at baseline and 1-year follow-up to assess for comorbidity improvement between cohorts. Compliance was evaluated by comparing exercise adherence rates.The pattern of weight loss and change in laboratory values was not different over time between the OOP group (n = 139) and NP group (n = 25). Patients lost an average of 14% (12.2–15.9) and 12.9% (9.3–16.5) of total body weight over all time points, respectively, in both groups (6, 12 and 24 months). Treatment adherence also did not differ between the groups.Having “skin in the game” by paying for ESG OOP does not correlate with better outcomes or treatment adherence, which further supports broad insurance coverage for this procedure.
Mechanisms of Gastroesophageal Reflux Post-Roux-en-Y Gastric Bypass: Universal Alteration of the Antireflux Barrier is the Culprit
Annan, Karim Al , Aburumman, Razan Nabeel Mousa, Abedalqader, Tala , Mrad, Rudy , Gala, Khushboo , Brunaldi, Vitor , Ghanem, Omar M. , Dayyeh, Barham K. Abu

Mayo Clinic

Surgical Laparoscopy, Endoscopy & Percutaneous Techniques | April 9, 2025 | Volume: 35 | Issue: 3 | Pages: No page available

10.1097/sle.0000000000001366 | PMID 40202306 Get It

Introduction: Gastroesophageal reflux disease (GERD) symptoms and the use of proton pump inhibitors (PPIs) remain prevalent after Roux-en-Y Gastric Bypass (RYGB), despite it being known to alleviate reflux. The physiological changes behind long-term GERD and hiatal hernia (HH) prevalence post-RYGB are not commonly investigated. Methods: In this consecutive cohort study, we examined patients who underwent RYGB and subsequent upper endoscopy, conducted by an expert bariatric endoscopist. The primary focus was on pouch endoscopic retrosflexion to evaluate the antireflux barrier (ARB). We gathered data encompassing patient demographics, anthropometrics, comorbidities, and findings from esophagogastroduodenoscopy (EGD) at the time of surgery and during follow-up EGD. Results: Our study included a total of 42 patients, predominantly female (97.5%) and White (100%), with an average age of 53.6±10.6 years and a body mass index (BMI) of 32.9±9.4 kg/m 2 . In our findings, all EGDs revealed the presence of a HH of varying sizes. The average HH size was 2.07±0.87 cm. The esophagogastric junction (EGJ) flap was also effaced in all patients with the majority (90.4%, 38 patients) classified as Hill grade IV and a smaller proportion (9.6%, 4 patients) as Hill grade III. Notably, PPI usage increased from the time of surgery to the time of EGD (69.0% vs. 42.9%, P =0.06). Conclusion: This research highlights the high incidence of HH and EGJ flap effacement in patients after RYGB, potentially elucidating the persistence of reflux symptoms, including weakly acidic or alkaline reflux, post-RYGB.
Choice of Anesthetic for Laparoscopic Bariatric Surgery Can Reduce the Use of Rescue Antiemetics in Postanesthesia Recovery Room: A Retrospective Observational Study
Šprung, Juraj , Ghanem, Omar M. , Lu, Lauren , Salame, Marita , Schroeder, Darrell R., Schroeder, Darrell R. , Lu, Lauren Y, Sprung, J , Schroeder, Darrell , Warner, David O. , Weingarten, Toby N.

Mayo Clinic

Surgical Laparoscopy, Endoscopy & Percutaneous Techniques | March 10, 2025 | Volume: 35 | Issue: 2 | Pages: No page available

10.1097/sle.0000000000001341 | PMID 40063267 Get It

Objective: Postoperative nausea and vomiting (PONV) is a frequent adverse event after bariatric surgery and is associated with patient dissatisfaction and increased health care burden. Aggressive multimodal antiemetic prophylaxis and the use of propofol infusion during anesthesia are associated with the reduction of PONV. In this study, we examined the use of rescue antiemetics following bariatric surgery performed with 3 different anesthetic strategies designed to reduce PONV: (1) primary volatile (VOL) anesthetic and propofol (PROP) infusion (VOL+PROP), (2) volatile anesthetic with propofol and dexmedetomidine (DEX) infusions (VOL+PROP+DEX), or (3) opioid-sparing total intravenous anesthesia (PROP+DEX). Methods: In this retrospective observational study, we included patients undergoing bariatric surgery from 2018-2022 who received 1 of 3 anesthetics: (1) VOL+PROP, (2) VOL+PROP+DEX, or (3) opioid-sparing PROP+DEX without a VOL. Inverse probability of treatment weighting analysis determined the association between the need for rescue-antiemetics in the postanesthesia care unit (PACU) and following PACU discharge. Results: Three hundred thirty-two patients received VOL+PROP, 354 VOL+PROP+DEX, and 166 PROP+DEX, and all received prophylactic antiemetics during surgery. After surgery, the PROP+DEX patients received fewer rescue antiemetics in the PACU compared with VOL+PROP (11% vs. 24%, P=0.002), and VOL+PROP+DEX fewer compared with VOL+PROP (16% vs. 24%, P=0.023). This differential antinausea effect was limited to PACU stay only. Rescue antiemetic use increased across all anesthetic management groups following PACU discharge until midnight on the day of surgery (ranging from 38% to 46% across groups, P=0.71) and through the first postoperative day (ranging from 47% to 57% across groups, P=0.20). Conclusions: The benefit associated with anesthetic strategies designed to reduce PONV was present but did not persist past PACU discharge. This finding suggests that aggressive perioperative multimodal antiemetic prophylaxis combined with anesthetic strategies designed to prevent PONV after bariatric surgery have only a short-lived effect, thus health care staff in hospital wards may expect to encounter high rates of PONV in these patients. There is a need for the development of novel antinausea treatments to reduce the rate of this frequent postoperative complication.
Hypoabsorption in Bariatric Surgery: Is the Benefit Worth the Risk?
Abedalqader, Tala , Jawhar, Noura , Gajjar, Aryan , Portela, Ray , Perrotta, Gerardo , Ghazal, Nour El , Laplante, Simon , Ghanem, Omar M. , El Ghazal, Nour , Laplante, Simon J , Perrotta, Gerardo

Mayo Clinic

Medicina | February 25, 2025 | Volume: 61 | Issue: 3 | Pages: 398

10.3390/medicina61030398 | PMID 40142209 Get It

Metabolic and bariatric surgery has been well described in the existing literature to be an effective and safe modality for weight loss in patients with obesity. Recently, hypoabsorptive procedures such as one-anastomosis gastric bypass (OAGB), biliopancreatic diversion with duodenal switch (BPD-DS), and single-anastomosis duodenoileostomy with sleeve (SADI-S) have gained traction, particularly among patients with severe obesity. These procedures combine restrictive and hypoabsorptive mechanisms, resulting in significant and sustainable weight loss, especially in those with severe obesity and associated comorbidities. However, the risk of malnutrition and nutritional deficiency following these procedures has been a deterrent for surgeons in their adoption. This review evaluates the existing literature on the safety, efficacy, and long-term outcomes of OAGB, BPD-DS, and SADI-S. While these hypoabsorptive procedures represent highly effective options for treating obesity, the associated nutritional complications necessitate the need for long-term follow-up and supplementation and highlight the need for careful patient selection.
Advances in Metabolic Bariatric Surgeries and Endoscopic Therapies: A Comprehensive Narrative Review of Diabetes Remission Outcomes
Ghusn, Wissam , Zeineddine, Jana, Betancourt, Richard S., Gajjar, Aryan , Yang, Wah , Ghanem, Omar M. , Betancourt, Richard S , Ghusn, Wissam , Yang, Wah , Robertson, Andrew G.

Mayo Clinic

Medicina | February 17, 2025 | Volume: 61 | Issue: 2 | Pages: 350

10.3390/medicina61020350 | PMID 40005466 Get It

Background and Objectives: Type 2 diabetes (T2D), closely associated with obesity, contributes to increased morbidity and mortality due to complications such as cardiometabolic disease. This review aims to evaluate the effectiveness of metabolic and bariatric surgeries (MBS) and endoscopic bariatric therapies (EBTs) in achieving diabetes remission and to examine key predictors influencing remission outcomes. Materials and Methods: This review synthesizes data from studies on MBS and EBT outcomes, focusing on predictors for diabetes remission such as preoperative insulin use, diabetes duration, HbA1c, and C-peptide levels. Additionally, predictive scoring systems, including the Individualized Metabolic Surgery (IMS), DiaRem, Advanced-DiaRem, ABCD, and Robert et al. scores, were analyzed for their utility in forecasting remission likelihood. Results: Key predictors of T2D remission include shorter diabetes duration, lower HbA1c, and higher C-peptide levels, while prolonged insulin use, and higher insulin doses are associated with lower remission rates. Scoring models like IMS and DiaRem demonstrate that lower scores correlate with a higher likelihood of remission, especially for procedures such as Roux-En-Y gastric bypass (RYGB). RYGB generally shows higher remission rates compared to sleeve gastrectomy (SG), particularly among patients with mild disease severity, while EBTs like ESG and IGBs contribute 5–20% total weight loss (TWL) and moderate glycemic control improvements. Conclusions: Both MBS and EBTs are effective for T2D management, with predictive scoring models aiding in individualized patient selection to optimize remission outcomes. Further research to validate these predictive tools across diverse populations could enhance treatment planning for both surgical and endoscopic interventions.
The Diabetes Remission Index
Ma, Pearl , Ikemiya, Kayla , Camilleri, Michael, Dayyeh, Barham Abu, Higa, Kelvin , Ghanem, Omar M. , Mundi, Manpreet, Hage, Karl , Ghusn, Wissam , Vierkant, Robert A. , Mundi, Manpreet S. , Fehervari, Matyas , Acosta, Andrés , Camilleri, Michael

Mayo Clinic

Annals of Surgery | February 4, 2025 | Volume: 284 | Issue: 1 | Pages: 91-98

10.1097/sla.0000000000006656 | PMID 39902562 Get It

Objective: To develop and validate 2 predictive models, the Diabetes Remission Index (DRI) and the Weight loss–adjusted DRI (W-DRI), for assessing type 2 diabetes (T2D) remission following metabolic and bariatric surgery (MBS). Background: MBS, including Roux-en-Y gastric bypass and sleeve gastrectomy, is highly effective in achieving T2D remission, but outcomes vary across populations. Predicting remission remains critical for individualized patient care and optimizing surgical outcomes. Existing tools focus on general outcomes, and a specific model incorporating weight loss data has been lacking. Methods: This multicenter, retrospective cohort study included patients with T2D and overweight/obesity (body mass index: ≥27 kg/m 2 ) who underwent Roux-en-Y gastric bypass or sleeve gastrectomy between 2008 and 2018. Institution 1 (I-1) data (n = 503) were used to develop and internally validate the models, whereas Institution 2 (I-2) data (n = 409) were used for external validation. The DRI model incorporated preoperative variables, and the W-DRI model, in addition, included postsurgical weight loss. Predictive accuracy was assessed using area under the Receiver Operating Characteristic curve [area under the curve (AUC)], calibration plots, and stratified analyses. Results: In I-1, 44.7% of patients achieved T2D remission, with a DRI model AUC of 0.80. In I-2, 52.6% achieved remission, with a model AUC of 0.78. Incorporating weight loss improved W-DRI predictive accuracy (AUC: 0.82 in I-1, 0.79 in I-2). Calibration plots demonstrated strong agreement between predicted and observed remission rates. An online DRI and W-DRI calculator is available through the Mayo Clinic webpage (https://newsnetwork.mayoclinic.org/dri-calculator/). Conclusions: The DRI and W-DRI models accurately predict T2D remission post-MBS, enabling personalized patient care and informed decision-making. Further validation across diverse populations is warranted.